Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Jamieson

Showing results (41-50 of 48) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 48 results.
British Journal of Cancer|November 11, 2017
Neutrophils: driving progression and poor prognosis in hepatocellular carcinoma?Jane Margetts, Laura F Ogle, Stephen L Chan, et al.
Cytometry. Part a : the Journal of the International Society for Analytical Cytology|February 25, 2020
Label-Free Leukemia Monitoring by Computer VisionMinh Doan, Marian Case, Dino Masic, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 27, 2019
Detection of Circulating and Disseminated Neuroblastoma Cells Using the ImageStream Flow Cytometer for Use as Predictive and Pharmacodynamic BiomarkersSwathi Merugu, Lindi Chen, Elizabeth Gavens, et al.
Nature Communications|July 1, 2026
Structural basis for independent pore function of Vpb4 from Bacillus thuringiensisRaymond Wirawan, W David Jamieson, Hannah M Baird, et al.
The Lancet. Oncology|September 9, 2017
Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trialBeatrice Seddon, Sandra J Strauss, Jeremy Whelan, et al.
Blood Advances|May 24, 2018
Inhibition of ATR acutely sensitizes acute myeloid leukemia cells to nucleoside analogs that target ribonucleotide reductaseSarah E Fordham, Helen J Blair, Claire J Elstob, et al.
Genes & Development|October 15, 2016
Condensin II mutation causes T-cell lymphoma through tissue-specific genome instabilityJessica Woodward, Gillian C Taylor, Dinesh C Soares, et al.
European Journal of Cancer (Oxford, England : 1990)|October 4, 2016
A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumoursDavid Jamieson, Melanie J Griffin, Julieann Sludden, et al.
Pageof 5

Showing results (41-50 of 48) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 48 results.
British Journal of Cancer|November 11, 2017
Neutrophils: driving progression and poor prognosis in hepatocellular carcinoma?Jane Margetts, Laura F Ogle, Stephen L Chan, et al.
Cytometry. Part a : the Journal of the International Society for Analytical Cytology|February 25, 2020
Label-Free Leukemia Monitoring by Computer VisionMinh Doan, Marian Case, Dino Masic, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 27, 2019
Detection of Circulating and Disseminated Neuroblastoma Cells Using the ImageStream Flow Cytometer for Use as Predictive and Pharmacodynamic BiomarkersSwathi Merugu, Lindi Chen, Elizabeth Gavens, et al.
Nature Communications|July 1, 2026
Structural basis for independent pore function of Vpb4 from Bacillus thuringiensisRaymond Wirawan, W David Jamieson, Hannah M Baird, et al.
The Lancet. Oncology|September 9, 2017
Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trialBeatrice Seddon, Sandra J Strauss, Jeremy Whelan, et al.
Blood Advances|May 24, 2018
Inhibition of ATR acutely sensitizes acute myeloid leukemia cells to nucleoside analogs that target ribonucleotide reductaseSarah E Fordham, Helen J Blair, Claire J Elstob, et al.
Genes & Development|October 15, 2016
Condensin II mutation causes T-cell lymphoma through tissue-specific genome instabilityJessica Woodward, Gillian C Taylor, Dinesh C Soares, et al.
European Journal of Cancer (Oxford, England : 1990)|October 4, 2016
A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumoursDavid Jamieson, Melanie J Griffin, Julieann Sludden, et al.
Pageof 5